EBITDA Margin % is calculated as EBITDA divided by its Revenue. Brooks Laboratories's EBITDA for the
three
months ended in Mar. 2026 was ₹20.2 Mil. Brooks Laboratories's Revenue for the
three
months ended in Mar. 2026 was ₹202.1 Mil. Therefore, Brooks Laboratories's EBITDA margin for the quarter that ended in Mar. 2026 was 10.02%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Brooks Laboratories EBITDA Margin % Related Terms
Brooks Laboratories EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Brooks Laboratories's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:533543 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Brooks Laboratories's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Brooks Laboratories EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Brooks Laboratories's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Brooks Laboratories's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Brooks Laboratories (BOM:533543) has a EBITDA Margin % of 10.02% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Brooks Laboratories and its competitors. According to the industry distribution chart, Brooks Laboratories ranks #113 out of 953 companies in the Drug Manufacturers industry, placing it in the top 11.9%.
Is Brooks Laboratories' EBITDA Margin % too high?
Brooks Laboratories' current EBITDA Margin % is 10.02%. The Drug Manufacturers industry median EBITDA Margin % is 12.49. Brooks Laboratories' value of 10.02% is 19.8% below this industry median. Based on the distribution chart, Brooks Laboratories ranks #113 out of 953 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Brooks Laboratories has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Brooks Laboratories' EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Brooks Laboratories ranks #113 out of 953 companies for EBITDA Margin %. This places Brooks Laboratories in the top 12% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.49. Brooks Laboratories' value of 10.02% is 19.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.49, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Brooks Laboratories's current EBITDA Margin % of 10.02% is 19.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Brooks Laboratories and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Brooks Laboratories's current EBITDA Margin % is 10.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brooks Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Brooks Laboratories (BOM:533543) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹117.81, compared to a current price of ₹77.71 — trading 34% below its estimated fair value. The current EBITDA Margin % is 10.02% and 19.8% below the Drug Manufacturers industry median of 12.49. Brooks Laboratories' overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Brooks Laboratories (BOM:533543), the current EBITDA Margin % is 10.02% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Brooks Laboratories (BOM:533543) Overvalued in 2026?
Based on GuruFocus' analysis, Brooks Laboratories stock appears to be undervalued.
The current stock price of ₹77.71 is trading 34% below its estimated GF Value™ of ₹117.81.
GuruFocus considers Brooks Laboratories to be Significantly Undervalued.
Key valuation signals for BOM:533543:
EBITDA Margin %: 10.02%
GF Value™: ₹117.81 vs. price of ₹77.71 (34% below fair value)
Industry Position: 19.8% below the Drug Manufacturers median (#113 of 953)
No single metric tells the full story. See the BOM:533543 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Brooks Laboratories Ltd is a pharmaceutical manufacturer focused on developing and producing a broad range of generic medicines. Its key segments include injectables, tablets, and dry syrups, with product lines covering antibiotics such as beta-lactams and cephalosporins as well as general critical care injectables. The company operates manufacturing facilities compliant with international quality standards located in India, serving both domestic and international markets. Revenue is generated through contract manufacturing and sales of pharmaceutical formulations distributed broadly across regulated and semi-regulated international markets. The company has obtained regulatory certifications from multiple countries to comply with international standards for pharmaceutical manufacturing.
67GF Score
Get the complete analysis for BOM:533543
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:533543 has been successfully added to your 
